Imagene, a leader in AI-powered Oncology Intelligence, today announced a collaboration with Tempus AI, Inc., a technology company leading the adoption of AI to advance precision medicine and patient care. The collaboration aims to advance cancer diagnostics by accelerating biomarker prediction, integrating AI-powered tools into clinical workflows, and enabling the commercialization of accessible diagnostic solutions.

Original from: Illumina · Core Illumina revenue of $1.1 billion for Q4 2024, up 1% from Q4 2023 on both a reported and constant currency basis; revenue of $4.3 billion for fiscal year 2024, down 2% fro..

Original from: Labcorp Company Provides 2025 Guidance · Results from Continuing Operations versus last year: - Revenue: Q4 of $3.33 billion vs $3.03 billion; Full year of $13.01 billion vs..

Original from: Siemens Healthineers Siemens Healthineers AG today announces its results for the first quarter of fiscal year 2025 ended December 31, 2024. Q1 Fiscal Year 2025 • ..

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced financial results for the fourth quarter and full-year 2024.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD's Biosciences and Diagnostic Solutions business from the rest of BD to enhance strategic focus and growth-oriented investments and capital allocation for both BD and the separated business and enhance value creation for shareholders.

AliveDx has obtained a CE mark under the EU’s in vitro diagnostic regulation (IVDR) for the AiPlex connective tissue disease (CTDplus) multiplex assay for use with its MosaiQ planar microarray platform.

Breast Cancer Companion Diagnostic Tests Human epidermal growth factor receptor 2 (HER-2) is an important driver gene and prognostic indicator for breast cancer. It is also a major predictor of anti-HER-2 therap..

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter of 2024.

Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2024. All results in this release reflect only continuing operations unless otherwise noted.

Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 29, 2024.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY® anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody* to identify patients with HR-positive, HER2-ultralow metastatic breast cancer who may be eligible for treatment with ENHERTU®. ENHERTU is a specifically engineered HER2-directed antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialised by Daiichi Sankyo and AstraZeneca.

Diatech Pharmacogenetics announced an expansion of its collaboration with Merck Serono Middle East Ltd., affiliates of Merck KGaA (“Merck”). The collaboration aims to improve patient access to RAS biomarker testing in the Middle East and Africa (MEA) regions.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2024.

Ovarian Cancer Companion Diagnostic Tests In 2019, the BRCA1 and BRCA2 Gene Mutation Detection Kit (Reversible Terminator Sequencing) of Xiamen Amoy Diagnostics Co., Ltd. was approved. It is intended for the qua..